EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Table 2 Prevalence and objective response rate of patients with different statuses of EGFR gene

Study	N	Prevalence (positive/total)				Objective Response Rate (responder/total)
		Amplification	High polysomy	Other GCN+	GCN-	Amplification	High polysomy	Other GCN+	GCN-
Campanella 2010²⁶	88	4/88		84/88		NR		NR
Frattini 2007²⁷	27	8/27	16/27	3/27		6/8	4/16	0/3
Gevorgyan 2007²⁸	40	8/40		19/40	12/40	0/8		0/19	5/13
Gonvalves 2008²⁹	29	0/29	2/29	10/29	17/29	NA	2/2	3/10	4/17
Italiano 2008¹⁵	41	0/41	8/41	2/41	31/41	NA	2/8	8/33
Lievre 2006³¹	30	3/30		27/30		3/3		8/27
Moroni 2005¹⁴*	29	7/29	2/29		20/29	6/7	2/2		1/20
Perrone 2009²⁴	31	2/31	21/31		8/31	1/2	4/21		4/8
Personeni 2008³³	87	2/87	31/87		54/87	2/2	15/31		8/54
Sartore-Bianchi 2007¹⁷	58	0/58		58/58		NA			6/58
Tol 2010³⁷	556	13/556	72/556		471/556	NR	NR	NR	NR

N, sample size; GCN+, increased gene copy number; GCN-, non-increased gene copy number; NR, not reported; NA, not applicable.
* This study did not specify the criteria for “amplification” explicitly. We applied the most popular criterion (gene/CEP7 ≥ 2, see Table 1) to categorize the patients of this study.

ISSN: 1756-8722